Project description
Given the strong scientific preclinical and clinical data indicating the potential of microbiota-altering therapies for PD are promising, and the anecdotal (case study) evidence that FMT works for these patients, there is an urgent need to reliably test this potential therapy in a randomized clinical trial.
Our study will be the first worldwide to investigate the potential therapeutic effect of FMT on symptoms and disease progression in patients with PD in a double-blind, placebo-controlled randomized clinical trial (source: https://clinicaltrials.gov).
Related projects
Towards a better understanding of a Gut-Vagina Axis by investigating the effects of Ramadan fasting on Gut and Vaginal Microbial Communities
Bacterial extracellular vesicles as biomarker for Parkinson's disease
Influence of gut microbiota composition and function on acute and persistent post-surgical pain
Study of the gut human microbiome and its relationship with immunosuppressive pharmacotherapy in stable renal transplant patients
The duodenal microbiome and effect of proton pump inhibitors in healthy volunteers and functional dyspepsia patients